Disease relevance of Cystadenocarcinoma, Serous

• In vitro and in vivo effects of prostaglandin D2 on human ovarian tumor growth were examined by using a cell line, designated HR, derived from ascites of a patient with serous cystadenocarcinoma of the ovary [1].
• Estrogen receptor alpha (ER-alpha) and beta (ER-beta) mRNAs in normal ovary, ovarian serous cystadenocarcinoma and ovarian cancer cell lines: down-regulation of ER-beta in neoplastic tissues [2].
• LOH of the TP53 marker was detected in 4 (44%) of 9 informative serous cystadenocarcinomas (SCa) but in 0 of 4 informative clear cell carcinomas (CCa) and 0 of 5 informative serous tumors of low malignant potential (SLMP) [3].
• RESULTS: Seladin-1 expression was identified in the normal ovary, mucinous cystadenocarcinomas and serous cystadenocarcinomas of the ovary whereas no expression was observed in the GCT [4].
• Three endometrioid adenocarcinomas and three serous cystadenocarcinomas had a PR level over 100 fmoles/mg protein [5].

High impact information on Cystadenocarcinoma, Serous

• Furthermore, DPPIV overexpression in SKOV3 cells, derived from serous cystadenocarcinoma, with little DPPIV expression induced a dramatic change in cellular morphology and a significant decrease in the abilities of both migration and invasion [6].
• We prepared Adriamycin-resistant and -sensitive cells from human ovarian serous cystadenocarcinomas [7].
• A cell-mediated cytotoxicity test, quantitated by postlabeling with tritiated thymidine, was used to asses immune reactivity of cancer patients to the HeW cell line derived from serous cystadenocarcinoma of the ovary [8].
• After the surgery, the tumor was diagnosed as serous cystadenocarcinoma of the ovary (stage IV) and 6 cycles of treatment consisting of cyclophosphamide, adriamycin and cisplatin (CAP) were performed [9].
• To test the hypothesis that GCT may exhibit loss of inhibin receptor expression we have examined the expression of the receptor subunits in a cohort of GCT and in mucinous and serous cystadenocarcinomas and normal ovary [10].

Chemical compound and disease context of Cystadenocarcinoma, Serous

• We report the antepartum use of cisplatin, followed by carboplatin, for an ovarian serous cystadenocarcinoma [11].
• RESULTS: Ninety-six patients who had optimal primary cytoreductive surgery for their stage IIIc serous cystadenocarcinomas of the ovary and had their estrogen and progesterone receptor status established were found [12].
• Except for melatonin, all neuroendocrine hormones used in this study inhibited proliferation of KF cells derived from human serous cystadenocarcinoma of the ovary in a dose-dependent manner [13].
• In all immunological tests, the specific immune sera against perchloric acid extracts of ovarian mucinous and serous cystadenocarcinomas and antisera against the reference antigens mentioned above were used [14].
• METHODS: One hundred thirteen formalin-fixed, paraffin-embedded sections were studied (30 benign ovarian endometriotic cysts, 24 endometriotic cysts containing endometrioid carcinomas, 19 endometriotic cysts harboring clear cell carcinomas, and 40 ovarian papillary serous cystadenocarcinomas) [15].

Biological context of Cystadenocarcinoma, Serous

• Centromere spreading (CS) of chromosomes and high occurrence of aberrations at centromeric region were observed in two papillary serous cystadenocarcinomas and one borderline papillary serous cystadenoma of the ovary [16].
• Prognostic significance of DNA ploidy and S-phase fraction in malignant serous cystadenocarcinoma of the ovary [17].
• Tissue distribution of the CA 125 determinant is most commonly seen in serous tumors of the ovary, with highest levels in borderline and frankly malignant serous cystadenocarcinomas [18].

Anatomical context of Cystadenocarcinoma, Serous

• Nature of carcinoembryonic antigen purified from malignant ascitic fluid of serous cystadenocarcinoma of the ovary [19].
• The object of this study was to analyse the tissue and serum metalloproteinase (MMP-2), an enzyme which degrades the basement membrane collagen type IV, as a potential marker useful in prognostic evaluation and clinical monitoring of the follow-up, in patients with advanced ovarian serous cystadenocarcinoma [20].
• Four cases of advanced stage (II or III) and one case of early stage (IC) borderline malignant serous cystadenocarcinomas of the ovary were maintained on culture dishes coated with an extracellular matrix (ECM) produced by bovine corneal endothelial cells [21].

Gene context of Cystadenocarcinoma, Serous

• Sixty serous cystadenocarcinomas were analyzed for their relative levels of EGFR and AR by Western blot analysis [22].
• Serous cystadenocarcinomas also had an unexpectedly high expression of COX-2 [23].
• Clinical significance of p21(WAF1/CIP1) and p53 expression in serous cystadenocarcinoma of the ovary [24].
• In serous cystadenocarcinomas, SP1 was present in 35.0% of cases, PP5 in 76.2%, PP10 in 9.5%, PP11 in 57.1% and PP12 in 23.8% [25].
• High CA125 values can be found in serous cystadenocarcinomas, CA125 can also be detected in patients with mucinous carcinomas [26].

Analytical, diagnostic and therapeutic context of Cystadenocarcinoma, Serous

• They had undergone optimal cytoreductive surgery for stage III grades 2-3 serous cystadenocarcinoma of the ovary, followed by six to nine cycles of cisplatin and cyclophosphamide chemotherapy and a negative second-look laparotomy [27].
• In the immunodiffusion test, rabbit antisera reacted with a heat-stable, perchloric-acid extractable antigen that was different from CEA and CA125 and possessed Hanganutziu-Deicher (HD)-type specificity in all 4 specimens of serous cystadenocarcinoma of the ovary [28].

References